Eczema Therapeutics Sector Forecast to Reach $49.8 Billion by 2035, Fueled by Breakthrough Biologics
The global eczema therapeutics sector is undergoing a significant transformation, propelled by the emergence of advanced biologic therapies and growing awareness around skin health. According to projections from Prophecy Market Insights, the sector is expected to surge from USD 19.5 billion in 2025 to USD 49.8 billion by 2035, reflecting a robust compound annual growth rate (CAGR) of 9.9%.
At the forefront of this shift is the increasing incidence of eczema—particularly atopic dermatitis—affecting millions globally. Characterized by chronic inflammation, severe itching, and skin barrier dysfunction, eczema is most common in infants and children but can persist into or begin in adulthood. In the United States alone, over 31 million individuals are living with eczema, as reported by the National Eczema Association.
Growth Catalysts
The rising prevalence of eczema is a primary factor behind the sector's momentum. Pediatric cases continue to climb, while adult diagnoses are also increasing as awareness and diagnostic capabilities improve. Urbanization and lifestyle factors are further contributing to the surge in cases across both developed and developing economies.
Recent years have seen a paradigm shift in treatment approaches, thanks to the approval and adoption of innovative biologics such as Dupixent (dupilumab) by Sanofi and Regeneron and Abrocitinib , a selective JAK1 inhibitor by Pfizer. These advanced therapies have proven especially effective for patients with moderate to severe eczema who do not respond well to conventional treatments like corticosteroids or calcineurin inhibitors.
Barriers to Access
Despite the progress, the eczema therapeutics landscape faces notable challenges. Chief among them is the high cost of biologic therapies, which can limit access, particularly in low- and middle-income regions. Additionally, traditional treatments, though widely used, often carry risks such as skin thinning and hormonal imbalances, which can deter long-term adherence and physician recommendations.
Opportunities in Innovation and Emerging Regions
The future of eczema care lies in personalized and targeted treatments. Innovations in genomics, microbiome research, and drug delivery are paving the way for more precise therapies with fewer side effects. Emerging economies present significant untapped potential, with expanding healthcare infrastructure, government support, and rising consumer awareness around dermatological conditions.
Sector Segmentation
The eczema therapeutics industry is segmented based on multiple parameters: By Drug Class: Including corticosteroids, calcineurin inhibitors, PDE4 inhibitors, and biologics.
Including corticosteroids, calcineurin inhibitors, PDE4 inhibitors, and biologics. By Treatment Type: Prescription medications, over-the-counter (OTC) products, alternative therapies, and home-based remedies.
Prescription medications, over-the-counter (OTC) products, alternative therapies, and home-based remedies. By Eczema Type: Atopic, contact, seborrheic, dyshidrotic, and nummular eczema.
Atopic, contact, seborrheic, dyshidrotic, and nummular eczema. By Route of Administration: Topical applications dominate, followed by oral and injectable options.
Topical applications dominate, followed by oral and injectable options. By Distribution Channel: Hospital pharmacies, retail outlets, and increasingly, online platforms.
Hospital pharmacies, retail outlets, and increasingly, online platforms. By Patient Demographic: Infants, children, and adults form the primary treatment groups.
Regional Outlook
North America remains the global leader, benefiting from advanced healthcare systems, strong R&D activity, and favorable insurance reimbursement models. Europe also demonstrates strong momentum, especially in nations such as Germany, France, and the UK. The Asia-Pacific region is emerging as the fastest-growing geography, driven by urbanization, increased healthcare spending, and rising patient volumes in countries like India and China.
Latin America, the Middle East, and Africa, while currently smaller in scale, are poised for steady progress as investments in healthcare infrastructure and dermatological services increase.
Competitive Landscape
The eczema therapeutics field is highly dynamic, with a blend of pharmaceutical giants and emerging biotech innovators. Key players include: Sanofi S.A.
Regeneron Pharmaceuticals
Pfizer Inc.
AbbVie Inc.
Novartis AG
LEO Pharma A/S
GlaxoSmithKline plc
AstraZeneca plc
Galderma SA
Incyte Corporation
These companies are actively developing new therapies aimed at improving efficacy, reducing side effects, and expanding access across age groups and severity levels.
Recent Developments Pfizer's oral JAK1 inhibitor Abrocitinib gained FDA approval in 2023, enhancing treatment options for patients requiring systemic therapy.
gained FDA approval in 2023, enhancing treatment options for patients requiring systemic therapy. Sanofi and Regeneron are expanding Dupixent's indications through clinical trials targeting adolescents and younger children.
indications through clinical trials targeting adolescents and younger children. A wave of startups is pursuing microbiome-focused and gene-based therapies that promise long-term, sustainable relief with minimal adverse reactions.
Looking Ahead
With innovation at the forefront, the eczema therapeutics sector is set for accelerated growth through 2035. Biologic advancements, expanding global awareness, and precision medicine are redefining treatment standards, offering renewed hope to millions living with this chronic skin disorder.
TIME BUSINESS NEWS
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
an hour ago
- Medscape
FDA Approves Dupilumab for Bullous Pemphigoid
Dupilumab has been approved by the FDA for the treatment bullous pemphigoid in adults, the manufacturer Regeneron announced. Dupilumab (Dupixent), a human monoclonal antibody that inhibits interleukin (IL)-4 and IL-13 signaling, is now approved in the United States for eight diseases, including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, and prurigo nodularis. Dupilumab, administered by subcutaneous injection, is the first targeted treatment to be approved in the United States for bullous pemphigoid, according to the company's press release. The approval follows a supplemental New Drug Application filed with the FDA in February 2025 and is based on data from ADEPT, a pivotal phase 2/3 study in more than 100 adults with moderate-to-severe bullous pemphigoid known as, according to Regeneron. The study's design was published in Advances in Therapy. In the study, 106 patients were randomized to 300 mg of subcutaneous dupilumab or a placebo injection every 2 weeks, added to standard-of-care oral corticosteroids. At 36 weeks, 18.3% of patients in the dupilumab group achieved the primary endpoint of sustained disease remission compared with 6.1% of those in the placebo group. The study defined sustained remission as a combination of complete clinical remission and no relapse after an oral corticosteroid taper by 16 weeks, with no use of rescue therapy during the study period. More patients treated with dupilumab achieved a clinically meaningful reduction in itching (38.3% vs 10.5%), and the median cumulative oral corticosteroid dose in the dupilumab-treated group was 2.8 g vs 4.1 g in the placebo group, according to the company release. The most common adverse events among patients receiving dupilumab (affecting 2% or more) compared with those receiving placebo were arthralgia, conjunctivitis, blurred vision, herpes viral infections, and keratitis. One patient receiving dupilumab also developed acute generalized exanthematous pustulosis; no cases were reported among those receiving placebo. The dupilumab study was funded by Sanofi and Regeneron, the companies co-developing dupilumab.
Yahoo
3 hours ago
- Yahoo
United States Diabetes Devices and Therapeutics Market Investment Opportunities Report 2025
The U.S. diabetes market is projected to grow at a CAGR of 7.2% from 2025-2029, reaching $39.33 billion. Key trends include real-time monitoring adoption, digital health integration, advanced delivery systems, and supportive regulatory frameworks. The report provides a data-centric analysis of market dynamics and opportunities. U.S. Diabetes Devices and Therapeutics Market Dublin, June 20, 2025 (GLOBE NEWSWIRE) -- The "United States Diabetes Devices and Therapeutics Market Investment Opportunities - Q2 2025 Update" report has been added to diabetes market in United States is expected to grow by 8.4% on annual basis to reach US$27.62 billion in diabetes market in the country has experienced robust growth during 2020-2024, achieving a CAGR of 9.1%. This upward trajectory is expected to continue, with the market forecast to grow at a CAGR of 7.2% during 2025-2029. By the end of 2029, the diabetes market is projected to expand from its 2024 value of USD 25.47 billion to approximately USD 39.33 billion. The U.S. diabetes devices and therapeutics market is undergoing significant shifts with real-time monitoring, digital integration, advanced delivery systems, and evolving regulatory support. These trends will intensify over the next 2-4 years, shaping clinical practices and reimbursement structures while emphasizing data integration and precise patient management. The U.S. diabetes devices and therapeutics market is characterized by a mix of established players and new entrants. Strategic partnerships, acquisitions, and the integration of digital health solutions are reshaping competitive dynamics. In the coming years, market consolidation and targeted innovation are expected to further define the competitive environment, influencing product offerings and patient management Adoption of Real-Time Glucose Monitoring U.S. healthcare providers increasingly use continuous glucose monitoring (CGM) systems to track patient glucose levels in real-time. Large healthcare networks have adopted CGM systems to support outpatient diabetes management. Recent publications indicate improvements in insurance reimbursement policies and favorable regulatory reviews. Enhanced clinical data on the reliability of CGM systems reinforces their use in routine diabetes care. Adoption is expected to increase, driven by wider coverage and enhanced device integration with electronic health records. The trend will likely intensify as more clinical studies validate the benefits of real-time monitoring in reducing long-term complications. Integrate Digital Health Solutions into Diabetes Management U.S. providers are integrating device data with telehealth platforms and remote patient monitoring systems for diabetes management. Examples include healthcare systems deploying centralized digital dashboards to monitor patient metrics remotely. Recent industry reports highlight a shift in healthcare delivery models that suggests a push toward digital transformation in chronic disease management. Insurance models increasingly support telehealth consultations and remote monitoring, aligning with broader medtech trends. The integration of digital platforms is expected to grow, promoting data-driven decision-making and enhancing care coordination. This trend will likely intensify, leading to a more efficient tracking of treatment adherence and patient outcomes. Advance Therapeutic Delivery Systems The market is witnessing the emergence of devices that support precise therapeutic delivery, such as smart insulin pens. U.S. manufacturers are introducing systems for accurate dosing and treatment adherence monitoring. Technological advancements in device miniaturization and data analytics are facilitating the development of these delivery systems. Recent healthcare publications note a rising focus on improving patient safety and treatment precision in diabetes care. Market penetration of smart delivery systems is expected to grow, influenced by evolving clinical practice guidelines and supportive reimbursement frameworks. This trend will intensify as precision therapy becomes a central focus in diabetes management. Regulatory and Reimbursement Frameworks Recent changes in FDA and CMS policies support integrating digital tools in diabetes care. Updated guidelines and expanded reimbursement criteria for digital health applications evidence these regulatory adjustments. Broader healthcare policy initiatives for cost containment and improved patient outcomes drive these regulatory changes. Publications from the past year highlight a response to the increased demand for remote monitoring and digital therapeutics. Regulatory support is expected to maintain momentum, enabling continued investment in digital health and advanced therapeutics. The framework will further intensify market adoption of compliant and data-integrated devices. Current Market ConditionsThe market comprises established manufacturers and emerging firms. A diverse portfolio of devices and therapeutics is present, ranging from established CGM systems to new smart delivery devices. Assess Key Competitors and Emerging Entrants Major companies, such as large medical device manufacturers and specialized diabetes care firms, hold significant market share. Established firms maintain comprehensive product portfolios covering both devices and therapeutics. New market entrants focus on integrating digital health solutions with diabetes management systems. These entrants bring targeted innovations, complementing the existing product mix in the U.S. market. Examine Strategic Partnerships and Corporate Activities Recent publications document acquisitions of smaller digital health companies by established device manufacturers. Strategic partnerships have been initiated between healthcare systems and technology firms to expand remote monitoring capabilities. The market shows signs of consolidation driven by competitive pressures and regulatory incentives. Collaborative efforts are aimed at enhancing integrated care delivery and data analytics capabilities. Future Competitive Dynamics Continued consolidation and strategic alliances are expected as established players seek to enhance their technological offerings. New entrants with digital health expertise will likely drive niche innovations, altering competitive positioning. Over the next 2-4 years, the competitive landscape will likely evolve with intensified competition and targeted market consolidation. Companies will increasingly leverage partnerships to improve patient data integration and therapeutic outcomes. Key Attributes: Report Attribute Details No. of Pages 50 Forecast Period 2025 - 2029 Estimated Market Value (USD) in 2025 $29.83 Billion Forecasted Market Value (USD) by 2029 $39.33 Billion Compound Annual Growth Rate 7.2% Regions Covered United States ScopeDiabetes Devices and Therapeutics Market Share by Category Diagnosis and Monitoring Devices Therapeutics Diabetes Devices and Therapeutics Market Share by Diagnosis and Monitoring Devices Blood Glucose Monitoring Devices Insulin Delivery Devices Diabetes Management and Mobile Applications Artificial Pancreas Devices Diabetes Devices and Therapeutics Market Share by Blood Glucose Monitoring Devices Self-Monitoring Blood Glucose Devices Continuous Blood Glucose Monitoring Devices Test Strips Lancets Diabetes Devices and Therapeutics Market Share by Insulin Delivery Devices Insulin Pumps Insulin Pens Insulin Syringes Diabetes Devices and Therapeutics Market Share by Therapeutics Oral Anti-Diabetic Drugs Insulin Non-Insulin Injectable Drugs Combination Drugs Diabetes Devices and Therapeutics Market Share by Oral Anti-Diabetic Drugs Alpha-Glucosidase Inhibitors DPP-4 Inhibitors SGLT-2 Inhibitors Diabetes Devices and Therapeutics Market Share by Insulin Basal or Long-Acting Bolus or Fast-Acting Traditional Human Insulin Drugs Insulin Biosimilars Diabetes Devices and Therapeutics Market Share by Non-Insulin Injectable Drugs GLP-1 Receptor Agonists Amylin Analogue Diabetes Devices and Therapeutics Market Share by Combination Drugs Combination Insulin Oral Combination Diabetes Devices and Therapeutics Market Share by Route of Administration Subcutaneous Intravenous Others Diabetes Devices and Therapeutics Market Share by Type of Diabetes Type 1 Diabetes Type 2 Diabetes Diabetes Devices and Therapeutics Market Share by Distribution Channels Online Pharmacies Hospital Pharmacies Retail Pharmacies Diabetes Devices and Therapeutics Market Share by End User Hospitals Diabetes Clinics Homecare For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment U.S. Diabetes Devices and Therapeutics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Yahoo
3 hours ago
- Yahoo
Medical Display Market to Reach USD 4.27 Billion by 2032, Driven by High-Resolution Imaging Demand and Digital Pathology Adoption
SNS Insider Highlights the Growth Trajectory of the U.S. Medical Display Market—Valued at USD 0.90 Billion in 2023—As North America Dominates Global Share with Advanced PACS Integration and Strong Adoption of Digital Imaging Technologies. Austin, June 20, 2025 (GLOBE NEWSWIRE) -- Medical Display Market Size & Growth Analysis: According to SNS Insider, the Medical Display Market was valued at USD 2.67 billion in 2023 and is projected to reach USD 4.27 billion by 2032, expanding at a CAGR of 5.37% over the forecast period of 2024–2032. Advanced Imaging Technologies and Digital Pathology Drive Robust Growth in the Medical Display Market The global medical display market is expected to grow steadily owing to rising demands for 4K high-resolution monitors (4K/8K) in fields such as radiology, surgery, and telemedicine. Each year, over 3 billion imaging procedures involving thousands of pictures, each requiring visual detection and interpretation, are performed, where enhanced picture quality is oxygen for the continued evolution of higher and maximum decision display a Sample Report of Medical Display Market@ The U.S. medical display market was estimated at USD 0.90 billion in 2023 and is expected to reach USD 1.38 billion by 2032, at a CAGR of 4.77% during the forecast period of 2024-2032. In North America, the U.S. dominates as a result of the advanced healthcare system with higher integration levels of digital imaging systems (PACS), and high adoption levels of newer diagnostic and surgical technologies It is also among the leader in healthcare R&D investments and an early adaptor of newer technologies such as AI-enabled and high-resolution displays. Major Players Analysis Listed in this Report are: Barco NV (Nio Gray 5.8 MP, MDSC-8532 4K UHD Display) EIZO Corporation (RadiForce RX660, RadiForce GX560) Sony Electronics Inc. (LMD-X550MT 4K 3D Display, PVM-2551MD OLED Monitor) LG Electronics (32HL512D-B 4K Surgical Monitor, 27HJ712C-W Clinical Review Monitor) Siemens Healthineers AG (ACUSON Sequoia Ultrasound System, Multix Impact Radiography System) Advantech Co., Ltd. (PAX-332 32 Surgical Monitor, PDC-W240 Medical Display) NEC Display Solutions (MD302C6 Diagnostic Display, MD212G3 Medical Monitor) AsusTek Computer Inc. (ProArt PA32UCX 4K Monitor, ProArt PA27AC HDR Monitor) BenQ Corporation (MD310C Diagnostic Display, PD3200U Designer Monitor) Dell Technologies Inc. (UltraSharp UP3218K 8K Monitor, UltraSharp U2718Q 4K Monitor) HP Inc. (Healthcare Edition HC270cr Clinical Review Monitor, Z27n G2 Display) ViewSonic Corporation (VG2448a 24" Monitor, VP3268-4K Professional Monitor) JVC Kenwood Corporation (CL-S600 6MP Diagnostic Monitor, MS-S500 5MP Monitor) WIDE Corporation (IF2105MP 5MP Diagnostic Display, IF2103MP 3MP Monitor) Nanjing Jusha Display Technology Co., Ltd. (C61W 6MP Diagnostic Monitor, M55W 5MP Monitor) Shenzhen Beacon Display Technology Co., Ltd. (M550G 5MP Diagnostic Monitor, M320G 3MP Monitor) FSN Medical Technologies (FS-P3102D 31 4K Display, FS-L2702D 27 HD Monitor) Axiomtek Co., Ltd. (MPC153-834 Medical Panel Computer, MPC240 24 Medical Panel PC) Coje Co., Ltd. (CME-261QA 26 Surgical Monitor, CME-191QA 19 Medical Monitor) Diva Laboratories, Ltd. (Diva DICOM Viewer, Diva Medical Image Server) Medical Display Market Report Scope Report Attributes Details Market Size in 2023 USD 2.67 billion Market Size by 2032 USD 4.27 billion CAGR (2024–2032) 5.37% U.S. Market 2023 USD 0.90 billion U.S. Forecast by 2032 USD 1.38 billion Base Year 2023 Forecast Period 2024–2032 Key Regional Coverage North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) Segment Analysis The Medical Display Market is Dominated by the Desktop Segment, By Device Type The desktop seized the largest share of the medical display market in the year 2023, with a 49% market share. These displays provide high-resolution output, DICOM compliance, and exact calibration of images, all important to provide accurate clinical interpretation. The seamless integration with PACS and multi-modality platforms, ergonomic design, and compatibility with advanced imaging software facilitate the adoption of desktop displays in hospitals and diagnostic centers, thus dominating the market share. The largest Share of the Medical Display Market by Application is held by the Digital Pathology Segment The digital pathology was the largest segment in the global medical display market with a 28% market share in 2023, primarily driven by the increased demand for whole slide imaging (WSI) and remote pathology solutions. Medical diagnosis based on digital pathology relies heavily on high-resolution, color-calibrated visuals for accurate assessment/analysis of tissue structures and cellular morphology; therefore, digital pathology visualizations must be faithful representations of the actual histopathological diagnosis. Pathology labs around the world have begun digitization of workflows around the themes of efficiency, education, and the use of artificial intelligence as an adjunct to diagnosis, and the growing trend has enabled a robust market for high-performance displays. For A Detailed Briefing Session with Our Team of Analysts, Connect with Us Now@ Medical Display Market Segmentation By Device Type Desktop Mobile All-in-one By Panel Size Type Up to-22.9-inch panels 23.0–26.9-inch panels 27.0–41.9-inch panels Above-42-inch panels By Resolution Up to 2MP 2.1 to 4MP 4.1 to 8MP Above 8MP By Application Digital pathology Radiology Multi-modality Surgical Mammography Others North America Leads the Medical Display Market, Asia Pacific Poised for Fastest Growth In 2023, the medical display market was led by North America with 42% market share, owing to the advanced healthcare infrastructure, increasing adoption of digital imaging technologies, and high demand for accurate diagnostic tools in radiology and surgery in the region. Presence of key display manufacturers and healthcare IT players and advantageous reimbursement policies for the healthcare sector drive the regional market. The Asia Pacific medical display market is expected to witness the highest growth during the forecast period, owing to an increase in healthcare spending, growth of hospital infrastructure, and rise in adoption of PACS and diagnostic imaging systems in emerging economies. With increasing speed, several countries such as those in Asia, having a population of billions (China, India, and South Korea), are moving towards the digitization of their healthcare sector with the support of government initiatives and a greater understanding of treatment at an early stage of the disease. Buy a Single-User PDF of Medical Display Market Analysis & Outlook Report 2024-2032@ Table of Contents – Major Key Points 1. Introduction 2. Executive Summary 3. Research Methodology 4. Market Dynamics Impact Analysis 5. Statistical Insights and Trends Reporting 6. Competitive Landscape 7. Medical Display Market by Device Type 8. Medical Display Market by Panel Size Type 9. Medical Display Market by Resolution 10. Medical Display Market by Application 11. Regional Analysis 12. Company Profiles 13. Use Cases and Best Practices 14. Conclusion About Us: SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world. CONTACT: Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK) Email: info@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
